Anti-Counterfeiting and Brand Protection News

Ahead of Pharma Brand Protection and Anti-Counterfeit Summit, we conducted an industry-wide survey to understand the threats faced by pharma manufacturers with regards to supply chain security and where they are prioritising investment in order to maximise their brand and product protection. 

The report provides a comparison of global and regional trends in brand protection strategy.

Download the full report now.

A new survey by Strategy&, PwC’s strategy consulting business, has found that pharmaceutical executives generally aren’t inclined to spend more to fight fakes, despite their awareness that current measures don’t go far enough. Not only do these executives misjudge their own vulnerability, but they also overlook the opportunities awaiting those that capitalize on rapidly evolving anti-counterfeiting technologies that do more than improve on existing supply chain safeguards. Companies that adopt these technologies will reap a range of new benefits, and gain an edge over rivals relying on yesterday’s solutions.

With this in mind, we decided to take a look at the top three reasons to capitalize on new anti-counterfeiting and brand protection technologies this year.

Estimates suggest that the global counterfeit drug market sits somewhere between US$75 and $200 billion and represents 10–50 percent of all drugs sold in some low-income countries. This article looks at the past, present, and future of counterfeit drug screening.

Ahead of the Pharmaceutical Brand Protection and Anti-Counterfeiting Conference, we took a look at INTERPOL's largest counterfeit seizures in 2018.

Download this piece to learn more about:

• Operation highlights from the U.S. Food and Drug Administration
• Trends deducted from this year's Pangea Enforcement Operation
• INTERPOL’S other major operations to combat the sale of illegal medicines online worldwide

Is your brand protection strategy compliant with the EU regulations in 2019?

As the EU FMD has recently come into full force, we wanted to understand what it would mean for serialisation managers and industry professionals, and how it will affect a pharmaceutical company's brand protection strategy.

In our exclusive interview with Ifigenia Dimitriadou, Manager Serialisation Operations and Logistics at Celgene, she shares her insights on what is happening post-FMD and what are realistic timelines for its implementation. Other topics include: 

• What serialisation managers should focus on now that serialisation is in place
• How companies are using data to drive their anti-counterfeiting and brand protection strategy 
• How serialisation roles are evolving into anti-counterfeiting and brand protection roles
• How a company should build its anti-counterfeiting and brand protection strategy – and where serialisation fits into this picture
• Plus much more. 

Fill in your details to download the full interview.